EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor

Vinayak Venkataraman iD, Suzanne George iD, Gregory M Cote iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, 2023. Verfasst von Vinayak Venkataraman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most gastrointestinal stromal tumors (GIST) are driven by activating mutations in Proto-oncogene c-KIT (KIT) or PDGFRA receptor tyrosine kinases (RTK). The emergence of effective therapies targeting these mutations has revolutionized the management of advanced GIST. However, following initiation of first-line imatinib, a tyrosine kinase inhibitor (TKI), nearly all patients will develop resistance within 2 years through the emergence of secondary resistance mutations in KIT, typically in the Adenosine Triphosphate (ATP)-binding site or activation loop of the kinase domain. Moreover, some patients have de novo resistance to imatinib, such as those with mutations in PDGFRA exon 18 or those without KIT or PDGFRA mutation. To target resistance, research efforts are primarily focused on developing next-generation inhibitors of KIT and/or PDGFRA, which can inhibit alternate receptor conformations or unique mutations, and compounds that impact complimentary pathogenic processes or epigenetic events. Here, we review the literature on the medical management of high-risk localized and advanced GIST and provide an update on clinical trial approaches to this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsAntineoplastic AgentsHumansImatinib MesylatePiperazinesPyrimidinesBenzamidesDrug Resistance, NeoplasmReceptor, Platelet-Derived Growth Factor alphaProto-Oncogene Proteins c-kitMutation

Stichwörter der Autor:innen

cancer diagnostics and molecular pathologynew drug development and clinical pharmacologysarcomas

Substanzen

Imatinib MesylateAntineoplastic AgentsPiperazinesPyrimidinesBenzamidesReceptor, Platelet-Derived Growth Factor alphaProto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Mass General Hospital Cancer Center, Center for Sarcoma and Connective Tissue Oncology, Boston, MA, USA.

ORCID-Profile: Vinayak Venkataraman, Suzanne George, Gregory M Cote

Zitieren

APA

Venkataraman, V., George, S., & Cote, G. M. (2023). Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor. The Oncologist. https://doi.org/10.1093/oncolo/oyad167

Vancouver

Venkataraman V, George S, Cote GM. Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor. The Oncologist. 2023. doi:10.1093/oncolo/oyad167

BibTeX
@article{Venkataraman2023,
  author = {Venkataraman, Vinayak and George, Suzanne and Cote, Gregory M},
  title = {Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad167}
}
Kostenlos starten →